Synonym
Phosphazide; AZT-5'-H2PO3; AZT-5'-Phosphonate; AZT-HP; Nicavir, Fosphazide, PZT, Phosphonavir
IUPAC/Chemical Name
Thymidine, 3'-azido-3'-deoxy-, 5'-(hydrogen phosphonate)
InChi Key
HXXOFKXVESEZNB-XLPZGREQSA-N
InChi Code
InChI=1S/C10H14N5O6P/c1-5-3-15(10(17)12-9(5)16)8-2-6(13-14-11)7(21-8)4-20-22(18)19/h3,6-8,22H,2,4H2,1H3,(H,18,19)(H,12,16,17)/t6-,7+,8+/m0/s1
SMILES Code
O=C(NC(C(C)=C1)=O)N1[C@H](O2)C[C@H](N=[N+]=[N-])[C@H]2COP(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
331.22
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Machado J, Salomon H, Oliveira M, Tsoukas C, Krayevsky AA, Wainberg MA. Antiviral activity and resistance profile of phosphazid--a novel prodrug of AZT. Nucleosides Nucleotides. 1999 Apr-May;18(4-5):901-6. PubMed PMID: 10432707.
2: Vorob'eva NN, Ivanova ES, Krasnoperova NN, Okishev MA. COMPARATIVE EFFICIENCY OF APPLICATION OF DIFFERENT THERAPEUTIC SCHEMES FOR POST-CONTACT PREVENTION OF HIV INFECTION IN HEALTH PROVIDERS. Klin Med (Mosk). 2016;94(4):295-299. PubMed PMID: 28957610.
3: Galegov GA. Phosphazide (nikavir) is a highly effective drug for the treatment of HIV/AIDS infection. Vopr Virusol. 2017;62(1):5-11. Review. PubMed PMID: 29323840.
4: Moshkovich GF, Minaeva SV, Varlova LW, Goryaeva MP, Gulyaeva SS, Tichonova EV. [CLINICAL AND PHARMACOECONOMIC RESULTS OF THE USAGE OF VARIOUS HIV REVERSE TRANSCRIPTASE INHIBITORS IN THE SCHEMES OF ANTIRETROVIRAL THERAPY OF PATIENT RECEIVING THERAPY FOR THE CHRONIC HEPATITIS C VIRUS]. Vopr Virusol. 2016;61(1):34-9. Russian. PubMed PMID: 27145599.
5: El-Sayed AA, Tamara Molina A, Álvarez-Ros MC, Alcolea Palafox M. Conformational analysis of the anti-HIV Nikavir prodrug: comparisons with AZT and Thymidine, and establishment of structure-activity relationships/tendencies in other 6'-derivatives. J Biomol Struct Dyn. 2015;33(4):723-48. doi: 10.1080/07391102.2014.909743. Epub 2014 Apr 24. PubMed PMID: 24762127.
